Overview

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Second Hospital

Treatments:

Albumin-Bound Paclitaxel
Paclitaxel